1132935-63-7
1132935-63-7 structure
- Name: ABT-333
- Chemical Name: dasabuvir
- CAS Number: 1132935-63-7
- Molecular Formula: C26H27N3O5S
- Molecular Weight: 493.575
- Catalog: Signaling Pathways Anti-infection HCV
- Create Date: 2016-02-27 12:31:06
- Modify Date: 2024-01-05 18:37:45
-
Dasabuvir (ABT-333) is a nonnucleoside inhibitor of the RNA-dependent RNA polymerase encoded by the HCV NS5B gene, inhibits recombinant NS5B polymerases derived from HCV genotype 1a and 1b clinical isolates, with IC50 between 2.2 and 10.7 nM.
| Name | dasabuvir |
|---|---|
| Synonyms |
ABT-333
Methanesulfonamide,N-(6-(5-(3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinyl)-3-(1,1-dimethylethyl)-2-methoxyphenyl)-2-naphthalenyl) ABT333 N-{6-[5-(2,4-Dioxo-3,4-dihydro-1(2H)-pyrimidinyl)-2-methoxy-3-(2-methyl-2-propanyl)phenyl]-2-naphthyl}methanesulfonamide Methanesulfonamide, N-[6-[5-(3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinyl)-3-(1,1-dimethylethyl)-2-methoxyphenyl]-2-naphthalenyl]- N-[6-[3-tert-butyl-5-(2,4-dioxopyrimidin-1-yl)-2-methoxyphenyl]naphthalen-2-yl]methanesulfonamide N-(6-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxyphenyl)naphthalen-2-yl)methanesulfonamide UNII:DE54EQW8T1 Dasabuvir |
| Description | Dasabuvir (ABT-333) is a nonnucleoside inhibitor of the RNA-dependent RNA polymerase encoded by the HCV NS5B gene, inhibits recombinant NS5B polymerases derived from HCV genotype 1a and 1b clinical isolates, with IC50 between 2.2 and 10.7 nM. |
|---|---|
| Related Catalog | |
| Target |
IC50: 2.2-10.7 nM (NS5B polymerase)[1] |
| In Vitro | Dasabuvir (ABT-333) is at least 7,000-fold selective for the inhibition of HCV genotype 1 polymerases over human/mammalian polymerases. Dasabuvir (ABT-333) inhibits the polymerase enzymatic activity of genotype 1 laboratory strain enzymes (H77, BK, N, and Con1 strains), as well as enzymes produced from polymerase genes from HCV genotype 1-infected subjects, with IC50s between 2.2 and 10.7 nM. Dasabuvir (ABT-333) inhibits replication of HCV subgenomic replicons in cell culture assays, with EC50 values of 7.7 and 1.8 nM against genotype 1a (H77) and 1b (Con1), respectively. In the presence of 40% human plasma, there is a 12- to 13-fold decrease in inhibitory potency, yielding EC50s of 99 and 21 nM for HCV genotype 1a (H77) and 1b (Con1) replicons, respectively[1]. |
| References |
| Density | 1.3±0.1 g/cm3 |
|---|---|
| Molecular Formula | C26H27N3O5S |
| Molecular Weight | 493.575 |
| Exact Mass | 493.167145 |
| PSA | 118.90000 |
| LogP | 3.68 |
| Index of Refraction | 1.641 |
| Hazard Codes | Xi |
|---|
|
~24%
1132935-63-7 |
| Literature: ABBOTT LABORATORIES Patent: WO2009/39134 A1, 2009 ; Location in patent: Page/Page column 109 ; |
|
~%
1132935-63-7 |
| Literature: ABBOTT LABORATORIES Patent: WO2009/39127 A1, 2009 ; Location in patent: Page/Page column 180 ; |
|
~%
1132935-63-7 |
| Literature: ABBOTT LABORATORIES Patent: US2012/14913 A1, 2012 ; Location in patent: Page/Page column 29-30 ; US 20120014913 A1 |
|
~%
1132935-63-7 |
| Literature: ABBOTT LABORATORIES Patent: US2012/14913 A1, 2012 ; US 20120014913 A1 |
|
~%
1132935-63-7 |
| Literature: ABBOTT LABORATORIES Patent: US2012/14913 A1, 2012 ; US 20120014913 A1 |
|
~%
1132935-63-7 |
| Literature: ABBOTT LABORATORIES Patent: US2012/14913 A1, 2012 ; US 20120014913 A1 |
|
~%
1132935-63-7 |
| Literature: ABBOTT LABORATORIES Patent: US2012/14913 A1, 2012 ; US 20120014913 A1 |
|
~%
1132935-63-7 |
| Literature: ABBOTT LABORATORIES Patent: US2012/14913 A1, 2012 ; US 20120014913 A1 |
